Answers are grounded in this paper and cite their sources.
728 Background: Oligometastatic disease (OMD) in pancreatic ductal adenocarcinoma (PDAC) is an emerging clinical entity. The limited extension of the disease prompt to explore the role of metastases-directed therapies (MDT); however, their actual survival and clinical benefits remain uncertain. Additional studies with larger effectives are needed to clarify the role of MDT in clinical practice. Methods: We conducted a retrospective multicenter, observational French-Belgian study to evaluate the impact of MDT on event-free survival (EFS) and overall survival (OS) in patients with OMD-PDAC. OMD was defined as metastases (mets) involving no more than 2 organ and ≤5 mets (Leonhardt CS. ESMO Open 2023). Eligible patients were adults with histologically confirmed PDAC who underwent a resection of the primary tumor, with concurrent or subsequent MDT of MDT. OS was defined as the delay from MDT to death from any cause; EFS was calculated from the date of MDT until radiologically confirmed disease progression, recurrence or death. The ALTOPANC score—based on known prognostic factors (CA 19-9 >90 U/mL, > 1 met, and non-pulmonary mets)—was correlated with OS and EFS. Results: Between 01/2011 and 12/2024, 155 patients with OMD-PDAC were included; 138 had metachronous metastases. Sites of mets included liver (n=71, 45%), lung (n=61, 39%), periaortic lymph nodes (n=13, 8%) and peritoneum (n=5, 3%). At time of the met's diagnosis, 107 patients (71%) had a single met, and 25 (17%) patients had presented two mets. After a median follow-up of 4.42 years, median EFS and median OS in the entire population were of 0.8 and 3,4 years respectively. MDT modalities consisted in surgery (n=69, 45%), radiotherapy (n=50, 32%), and thermoablation (n=36, 23%). In the multivariate Cox model, higher CA 19-9 level (HR = 1.29, 95% CI: 1.13–1.48, p = 0.0002) and the presence of 2 (HR = 2.54, 95% CI: 1.32–4.88, p <0.0001) or ≥3 treated mets (HR = 4.39, 95% CI: 2.18–8.84, p <0.0001) were independent adverse prognostic factors for OS. Thermoablation was independently associated with an improved OS compared to other technics (HR=0.51, 95%CI: 0.27–0.96, p =0.0127). The ALTOPANC score was significantly associated with EFS :2-year EFS rates were 53.1%, 23.8%, 8.3%, and 0% in patients with scores of 0, 1, 2, and 3, respectively (p < 0.001). A similar trend was observed for OS. Conclusions: 1) This real-world, study shows promising results of MDT in patients with OMD-PDAC, particularly thermoablation ; 2) among patients with favorable prognostic profile (low ALTOPANC score) may have the higher benefit. A prospective randomized study is warranted to confirm these results.
No takes yet. Share an insight, caveat, or question.
Parent et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: